|JWH-133||liver in rats via experiment||The protective effect of cannabinoid type 2 receptor activation on renal ischemia-reperfusion injury||Aug 2019|
|The JWH-133 application at three different doses decreased the glomerular and tubular damage. Additionally, in the renal tissue, nuclear factor-kappa-B, tumour necrosis factor alpha, interleukin-1beta, and caspase-3 levels decreased immunohistochemically. Similarly, JWH-133 application decreased the serum tumour necrosis factor alpha, blood urea nitrogen, creatinine, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, Cystatin C, interleukin-18, interleukin-1beta, interleukin-6, and interleukin-10 levels.|
|WIN55,JWH-133||cancer,skin cancer in mice via experiment||Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors||Jan 2003|
Action Pathway: CB2|
Local administration of the mixed CB1/CB2 agonist WIN-55,212-2 or the selective CB2 agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice
|JWH-133||liver in mice via experiment||Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury||Feb 2007|
|These findings suggest that oxidative/nitrosative stress and inflammatory stimuli may trigger endocannabinoid production, and indicate that targeting CB2 cannabinoid receptors may represent a novel protective strategy against I/R injury|
|JWH-133||cancer,glioma in mice via experiment||Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.||Aug 2001|
Ingestion Method: 50 microg/day|
Action Pathway: CB2
Experiments carried out with C6 glioma cells in culture evidenced the internalization of the CB(2) but not the CB(1) receptor upon JWH-133 challenge and showed that selective activation of the CB(2) receptor signaled apoptosis via enhanced ceramide synthesis de novo. These results support a therapeutic approach for the treatment of malignant gliomas devoid of psychotropic side effects.
|JWH-133||pain,arthritis in rats via experiment||Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint.||Nov 2013|
Action Pathway: CB2|
These data provide new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated combined with converging pre-clinical evidence that activation of CB2 receptors inhibits centralsensitization and its contribution to the manifestation of chronic OA pain. These findings suggest that targeting CB2 receptors may have therapeutic potential for treating OA pain.